VEGFA and hypertensive disorder: Preclinical evidence suggested HTN may impair anti-PD-1 response through angiotensin II-mediated CD8+T cell suppression and vascular endothelial growth factor-driven myeloid-derived suppressor cell accumulation (34, 35).